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Abstract
Depression is  a widely observed psychiatric  disorder  that  affects  a quite  large number of
people all around the world. A major depressive disorder (MDD) is a multifactorial disease
that IS associated with fluctuations in appetite, body weight, and energy situations in addition
to serious mood problems. The aim of this review is to investigate a possible link between
energy regulatory hormones of irisin and depressive disorders. 
Irisin  is  a  hormone  that  plays  a  significant  role  in  the  regulation  of  lipid  and  glucose
metabolism in skeletal muscle and adipose tissue. 
Irisin was also reported to play significant roles in the central nervous system. In the literature
there are reports indicating a beneficial antidepressant role of irisin in MDD. 
It  should be emphasised that  the antidepressive effects  of  exercise could be the result  of
exercise-induced increased hormones of irisin.
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Introduction
Depression/major  depressive  disorder  (MDD)  is  a  disease  that  has  genetic,
biochemical,  and  neurophysiological  causes  and  consequences,  and  is  characterized  by
feelings such as nervousness, insecurity, hopelessness, worthlessness, and guilt. In addition,
1
symptoms such as decreased ability to concentrate and think, decreased or increased appetite,
weight  loss  or  weight  gain,  insomnia  or  hypersomnia,  low  energy,  fatigue  or  increased
agitation,  decreased  interest  in  pleasurable  stimuli  (anhedonia),  and  recurrent  thoughts  of
death  and  suicide  may  occur.  It  is  a  mood  disorder  [1,  2].  In  2008,  the  World  Health
Organization stated that  MDD held third place worldwide in  terms of disease burden but
predicted that it will be in first place by 2030 [3]. The general prevalence of MDD in society
is 15%; it is one of the most common psychiatric disorders in women, with a rate of 25%.
With the COVID-19 virus outbreak in 2020, these rates have increased significantly,  with
many researchers reporting a sudden increase in stress, anxiety, and depression and a further
progression of existing psychiatric disorders [4–7]. The potential roles of energy regulatory
hormones in patients with depressive disorders and neuropsychiatric function have become a
topic of interest in clinical medicine [8, 9]. Irisin is a recently discovered muscle-released
myokine,  and  its  relationship  with  depression,  as  well  as  many  other  diseases,  is  being
investigated.  This  review  aims  to  examine  the  physiological  relationship  between  2
phenomena that have attracted attention, especially recently.
The history of irisin
Irisin  was  discovered  in  2012  as  a  hormone  released  from  the  muscle  cells  of
transgenic mice encoding a gene in a genomic study examining the PPARGC1A gene [10].
The Ppargc1a gene is responsible for encoding the peroxisome proliferator-activated receptor
gamma coactivator 1-alpha PPAR-γ co-activator-1 α (PGC-1α) transcription cofactor, which
plays a key role in various body systems [10]. In a study in the literature, when a mouse model
that overexpressed PGC-1α was studied, it strongly increased the expression of fibronectin
type III domain 5 (FNDC5) proteins. Later, it was understood that this myokine, which was
discovered as a thermogenic protein that causes energy expenditure by turning white adipose
tissue into brown adipose tissue, was actually released into the bloodstream by cleavage of the
membrane protein called FNDC5 in the muscles. This proteolytic product with 112 amino
acids, which is formed by the breakdown of 212 amino acid FNDC5 protein, is called “irisin”.
The name irisin comes from the name 'Iris', the messenger goddess in Greek mythology [10].
Biochemical structure and secretion of irisin
Irisin is a protein-structured hormone secreted from muscle tissue, with a molecular
weight of 12 kDa, containing 112 amino acids [10]. This hormone-like myokine is secreted
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from skeletal muscle into circulation as a product of FNDC5 in response to exercise. FDNC5,
which can also be referred to as FRCP2 or PeP protein, was first identified as a receptor in
2002, and it was stated to be critical for the differentiation of myoblasts and neurons [11, 12].
However, studies on FNDC5 remained scarce until the discovery of irisin.
The FNDC5 protein  consists  of  a  209 amino  acid  primary structure,  hydrophobic
transmembrane domain, and a C-terminal domain, and it serves as a signal peptide [11]. The
first 29 amino acids that make up the primary structure of mouse FNDC5 are a signal peptide,
followed by the fibronectin III (FNIII) domain consisting of 94 amino acids, and the next 28
amino  acids  have  unknown  structure  and  function.  This  28-amino-acid  site  contains  the
putative cleavage site for irisin. Next comes a 19-amino-acid transmembrane domain and a
39-amino-acid cytoplasmic domain. As a result, FNDC5 is a type-I transmembrane protein the
FNIII domain of which is extracellular [13]. Part of the extracellular N-terminal is cleaved
and released into circulation [10]. The cleavage process of irisin derived from the extracellular
domain of FNDC5 and the enzymes that mediate this process have not been fully elucidated.
The  structure  of  irisin  consists  of  an  N-terminal  FNIII-like  domain  attached  to  a
flexible C-terminal tail. This area forms a continuous subunit-leaf dimer that has not been
seen before [14]. It was preserved throughout the evolutionary process and is 100% similar in
mice and humans [10].
In addition, irisin was accepted as an exercise-dependent myokine based on the up-
regulation of FNDC5 in mouse skeletal  muscle  after  exercise  [10].  Although it  is  mainly
found in perimysium and endomysium in skeletal muscle, it  was detected in heart muscle
(pericardium),  brain,  cerebrospinal  fluid,  optic  nerve,  tongue,  and rectum and,  to  a lesser
extent, testicles (Sertoli and Leydig cells), pancreas, liver, spleen, and stomach tissues [15,
16]. In addition, due to the presence of irisin in the cerebellum, it was suggested that the
cerebellum may be a neural circuit that can regulate adipocyte metabolism and connect it to
adipose tissue [17].
FNDC5 is  also  expressed  in  the  brain  [11,  12].  Exercise  induces  FNDC5 in  the
hippocampus dependent on PGC-1α, which leads to increased BDNF expression [18, 19].
BDNF is a powerful regulator of neurogenesis, synaptogenesis, and synaptic plasticity [20]. In
many studies, it was stated that exercise has beneficial effects on brain health and cognitive
skills and improves results in neurological conditions such as depression, epilepsy,  stroke,
Alzheimer’s  and  Parkinson’s  disease  [21–25].  Accordingly,  it  was  suggested  that  the
molecular mediator of exercise-dependent neurogenesis may be FNDC5/irisin.
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Because  of  its  presence  in  many tissues,  irisin,  like  many other  molecules,  is  not
specific and cannot be thought of as just a myokine. In addition, it was stated in a study that it
also secretes FNDC5 from white adipose tissue, so the irisin is not only a myokine but also an
adipokine  [26,  27].  Approximately  72%  of  FNDC5/irisin  in  circulation  was  previously
released due to muscle secretion [28]. Exercise-induced increases of circulating irisin levels
have been shown in many studies [10, 29, 30]. In addition, improved depression conditions in
MDD patients following exercise programs have been reported [31, 32].
Irisin’s mechanism of action
Irisin  is  differentiated  from  the  FNDC5  molecule,  which  is  membrane-bound  in
skeletal muscle, by the trigger of exercise and muscle movements [33]. When the N-terminal
part is cleaved and released as irisin, the C-terminal domain of FNDC5 remains in the cell
[33]. Irisin shows its effect on white adipose tissue by stimulating brown fat-like genes, but its
receptor has not yet been discovered [10]. In addition, irisin can cross the blood-brain barrier
and affect the central nervous system [34].
The first mechanism of action is that after binding to the hormone receptor, it activates
the  cyclic  adenosine  mono  phosphate  (cAMP),  protein  kinase-A (PKA),  and  hormone
sensitive lipase (HSL)/perilipin pathway,  which ensures fat  breakdown.  Adenylate  cyclase
enzyme is activated first in the cell membrane, and cAMP increase occurs inside the cell. The
increasing  cAMP level  activates  PKA.  PKA induces  phosphorylation  of  both  HSL and
perilipin.  Perilipin  is  a  protein  found  on  the  surface  of  lipid  droplets  that  reduces  fat
breakdown. HSL allows the stored lipid droplets to move from the cytosol in order to lipolyze
perilipin.  Irisin-induced  down-regulation  of  perilipin  and  up-regulation  of  HSL increase
lipolysis [35].
The second mechanism of action is that irisin stimulates the nucleus in an unknown
way,  increasing  UCP1 expression  and  blocking  ATP production  in  the  electron  transport
system, increasing  heat  production.  Increased  heat  production with the increase  of  UCP1
expression increases energy expenditure in terms of glucose/fat metabolism. It also provides
activation of HSL [10, 35].
Physiological effects of irisin
White and brown fat cells are different from each other. While white adipose tissue
stores energy as fat,  brown adipose tissue distributes energy as fatty acids and accelerates
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energy burning [36]. Irisin causes the white adipose tissue to convert to brown [10]. As a
result of the transition from white adipose tissue to brown, fat and glucose metabolism is
mainly affected. This is important because it can be associated with many metabolic disorders
such as obesity and type 2 diabetes.
In addition, irisin regulates the mechanism of body temperature.  In rodents, brown
adipose tissue releases heat with the effect of UCP1 in thermogenesis without shivering [37].
If the heat demand cannot be met sufficiently by thermogenesis without shivering, shivering
comes into play. In this way, heat begins to be produced from muscle contractions [38]. Irisin
induces thermogenesis by both increasing UCP-1 expression and stimulating the browning of
adipocytes. As a result, through these effects, irisin ensures energy expenditure and regulates
browning of adipocytes, thermoregulation, and glucose homeostasis [10].
In  addition,  irisin,  which  is  a  myokine,  induces  genes  that  regulate  the  energy
mechanism of the cell by acting on skeletal muscle, causing an increase in energy expenditure
and oxidative metabolism. FNDC5 expression and release of irisin increase during myogenic
differentiation in myocytes via the ERK pathway [39]; this affects the glucose metabolism by
increasing glucose uptake into the muscle via GLUT4 via the AMPKα2 pathway accompanied
by p38MAPK-GLUT translocation in differentiated skeletal muscle cells [39].
Direct association of irisin and depression
Different studies are still being conducted about the possible effects of irisin. Studies
on FNDC5 and PGC-1α, from which irisin originates, constitute these possible effects. The
hippocampus and ventral tegmental area (VTA), from which FDNC5 was seen to be released,
was found to be effective on the proactive learning style (with the use of the reward signal)
[40, 41]. The relationship between dopaminergic neurons of the mesolimbic system in the
reward-related learning process is known [42]. These neurons play a role in the regulation of
mood, motivation, reward, pleasure, and arousal by secreting dopamine [43]. Moreover, the
rewarding effects of addictive pharmacological agents such as alcohol, nicotine, cocaine, and
heroin are associated with mesolimbic dopaminergic neurons [44, 45].
In addition to its direct effect, BDNF, which increases the expression of FNDC5 the
precursor of its irisin, also plays a role in regulating the function of dopaminergic neurons.
BDNF increases the dopaminergic effect by activating the presynaptic dopamine-3 receptors
in VTA and the kinase B receptor associated with tropomyosin [41]. In this way, it modulates
dopamine release related to neuronal plasticity, and plays an effective role in learning and
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memory [46]. Besides many other effects, mesolimbic dopamine plays an important role in
the reward pathway, such as mediating severe social stresses [47].
Although it is still not known how BDNF affects the mesolimbic reward pathway, it
was determined that activation of this pathway increases the amount of BDNF in the nucleus
accumbens (NAc) and that CRF here mediates the stress transition [48]. Studies about the
role/condition of the brain's mesolimbic circuitry in stress regulation and depression show that
exposure to a single uncontrollable deterrent experience causes impairment in response to
rewarding/deterrent  stimuli  and  inhibition  of  dopamine  release  in  rewards  [49].  It  was
reported that chronic stressful experiences can reduce the ability of stressors by disrupting
their  behaviour,  induce  behavioural  sensitivity  to  psychostimulants,  and  cause  adaptive
changes in mesolimbic dopamine function [49]. 
In a recently published study comparing athletes with a control group, the level of
irisin was inversely correlated with mild depression and low-grade white matter lesions in the
brain  [50].  However,  a  study  performed  in  obese  women  showed  no  association  with
depressiveness and plasma irisin levels [51].
The role of irisin in the physiopathology of depression
In order  to  understand the role  of  irisin  in  the pathophysiology of  depression,  the
physiopathology of depression should be examined first. Although there are several theories
about this, it is still not fully elucidated. These theories are largely based on the dysregulation
of  the  hypothalamic-pituitary-adrenal  (HPA)  axis  and  the  hippocampus,  and  include
neurotransmitters  such  as  corticotropin-releasing  hormone  (CRH),  glucocorticoids,  brain-
derived neurotrophic factor (BDNF), and dopamine [52].
Stress, particularly interpersonal stress, is one of the strongest proximal risk factors for
depression [53]. In depressed individuals, profound differences in behaviour may occur with
the onset of symptoms such as sad mood, anhedonia, decreased motivation, decreased energy
level, fatigue, and social-behavioural withdrawal [47, 53]. The physiological mechanism of
these behavioural changes and its relationship with irisin was investigated in many different
studies.
In one  study,  anhedonia,  one  of  the  main  symptoms of  major  depressive  disorder
(MDD),  was  associated  with  decreased  sensitivity  to  reward  [54].  In  addition,  Wu et  al.
reported that the hypermetabolism of BDNF may be a function of anhedonia rather than other
features in MDD in a study comparing MDD patients with and without anhedonia [55].
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In a study investigating social withdrawal/non-communication (another symptom of
MDD), mice exposed to repetitive aggression displayed reluctance for social communication,
and BDNF was necessary for this response [56].
In a study in the literature involving stroke patients, low serum irisin level was found
to  be  associated  with  post-stroke depression  (PSD) [57].  In  another  study with  bronchial
asthma patients, distress disorder (a general term that includes MDD), which is the most well-
known comorbidity of bronchial asthma, was found in very few/no patients with higher serum
irisin and BDNF [58]. According to these data, a high serum irisin level decreases the risk of
developing MDD.
The therapeutic effect of irisin on depression
In addition to the MDD physiopathological role of irisin, its therapeutic effects were
also investigated. Irisin injections were given to rats with chronic unpredictable stress. As a
result of this application, irisin regulated energy metabolism in the prefrontal cortex of the
brain  and  exerted  antidepressant-like  effects  in  rats  [59].  Antidepressants  work  with  the
principle of increasing BDNF expression and preventing stress-induced BDNF decrease by
increasing BDNF mRNA through 5-HT2A and β-adrenoceptor subtypes. Neurotrophic factors
such as BDNF or neurotrophin-3 (NT-3) increased the function of 5-HT-containing neurons in
the rat brain and stimulated their growth [60]. In terms of increasing BDNF expression, irisin
shows similar effects, using a similar pathway to antidepressant drugs.
Various studies were conducted on this with different patient populations. As a result
of the high rate  of depression in post-operative patients,  irisin treatment was used in one
study. It was reported that irisin reduces depressive symptoms in mice exposed to propofol
used  for  general  anaesthesia,  inhibits  propofol-induced  neuronal  cell  death,  and  inhibits
cytokine release from astrocytes  61. In addition, epidermal growth factor receptor (EGFR),
which is proven to play a role in the pathogenesis and progression of different cancer types,
was reported to reduce the propofol-dependent increase in surface expression [61, 62]. In a
study in the literature, mice were injected with central irisin. Likewise, an antidepressant-like
effect was achieved. In addition, it was reported to enhance the expression of PGC-1α mRNA
( which controls mitochondrial biogenesis and oxidative metabolism) in the hippocampus and
prefrontal cortex [63, 64]. PGC-1α also acts as a potent ROS removal regulatory antioxidant
by  increasing  the  expression  of  many  ROS  detoxifying  enzymes,  and  it  appears  to  be
associated with prevention of neurodegenerative disorders such as aging [63]. This effect is
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also important in terms of the risk of MDD development; various experimental protocols in
humans  and  animals  showed  that  inflammation  and  neuroinflammation  combined  with
external stimuli and neurophysiological mechanisms can trigger the formation of MDD [65].
Increasing  the  expression  of  PGC-1α  decreases  both  the  synthesis  and  release  of
proinflammatory cytokines and glutamatergic neurotoxicity [65].
There  are  many studies  in  the  literature  about  the relationship  between MDD and
physical exercise that secretes irisin. In a study conducted on patients with mild/moderate
MDD, physical exercise had an antidepressant-like therapeutic effect [66]. In another study,
moderate  aerobic exercise was performed by MDD patients for 8 weeks;  while  cognitive
improvements were observed in the patients, it was reported that depression scores decreased
[67].  In  addition,  in  a  study  comparing  healthy  individuals  and  MDD  patients,  subjects
exercised and hippocampal activity was examined by neuroimaging methods. Exercise was
found to promote neuroplasticity in both healthy and depressed brains [68]. In addition, it can
increase  neuronal  efficiency in  individuals  with  low compliance  and cause  a  great  mood
change in patients with MDD [68]. However, contrary to the literature, in a study conducted
on obese women, irisin was not associated with depression, anxiety, perceived stress level,
and eating disorders [51].
Some  studies  reported  that  exercise  has  antidepressant-like  effects.  However,  the
mechanisms mediating  this  effect  have not  been fully explained.  Possible  mechanisms of
action such as reducing neuroinflammation and peripheral  inflammation and affecting the
reward pathway in the mesolimbic cerebral were emphasized [69]. Some studies show that
physical exercise promotes changes in the monoaminergic neurotransmission circuit, one of
the main mechanisms of MDD and antidepressant treatments, through its effect on the release
of proinflammatory cytokines [65, 70].
With  recent  advances,  researchers  examined  the  FNDC5  C-terminal  and  irisin
fragment to explain this mechanism. In a study, immunohistochemical analyses and staining
were performed in all hippocampal areas in mice that underwent a physical exercise protocol.
There was an increase in cell proliferation, neuronal differentiation, and neuronal survival in
the  dorsal  and ventral  dentate  gyrus.  In  addition,  the  duration  of  immobility,  one  of  the
depressive symptoms, was reduced in mice. Finally, exercise also increased the number of
FNDC5-positive cells in the hippocampal dentate gyrus and the immune content of FNDC5
C-terminal  and  FNDC5/irisin  in  the  whole  hippocampus.  The  FNDC5  C-terminal
fragment/irisin  pathway was  reported  to  have  an  antidepressant-like,  pro-neurogenic,  and
8
neuroprotective effect through treadmill running [71]. The dentate gyrus is the hippocampal
area responsible for the regulation of cognitive and emotional behaviour [72]. Therefore, the
increase  of  FNDC5/irisin  in  this  area  indicates  that  irisin  may be  effective  in  regulating
emotional  behaviour.  In  addition,  it  was  suggested  that  the  beneficial  effects  of  physical
exercise on MDD are likely to be mediated by the FNDC5/irisin pathway.
Possible relationship between irisin and depression
Due to the effects of irisin on glucose and lipid metabolism, the situation in many
diseases is a topic of curiosity for many researchers and has been the subject of many studies.
It was suggested that irisin, which is introduced with the “sport in the pill” discourse, can
provide many of the positive effects of sports on health in a short time [10]. First of all, it was
seen as a promising solution for diseases such as obesity and type-2 diabetes mellitus (T2DM)
and was the subject of research. Considering that the most common diseases accompanied by
depression are obesity and T2DM, a possible relationship should be examined.
Obesity, depression, and irisin
Although obesity and MDD are very common, the physical and psychiatric conditions,
causal  pathways,  or mechanisms that  link them have not yet  been elucidated [73,  74].  In
addition to studies suggesting that obesity causes MDD, there are studies reporting that the
negative treatment of MDD triggers obesity or that they occur concurrently [74–76]. Although
there are different theories about underlying factors, it was reported in the literature that there
is a significant positive relationship between these 2 diseases with a high prevalence [77–79].
It would also be useful to look at the relationship between exercise, irisin, and depression in
terms of obesity.
In many studies, it was found that the irisin levels of obese people are significantly
reduced in terms of circulating irisin levels compared to healthy individuals [26, 80].
Some studies  suggested  that  muscle  FNDC5 gene expression in  humans  increased
with obesity, and it was reported that irisin decreased as a result of weight loss after bariatric
surgery  [15,  81].  However,  Huh  et  al.  also  reported  that  this  relationship  may  be  a
compensatory mechanism [15].
Although there are many studies in the literature that examine the relationship between
MDD and irisin,  and obesity  and irisin,  there  is  no  study that  compares  the  relationship
between MDD, obesity, and irisin, which progresses with common mechanisms.
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Type 2 diabetes mellitus, depression, and irisin
A similar relationship to the obesity/MDD relationship is seen between T2DM and
MDD. They have identical mechanisms feeding each other and are mutually seen as risk
factors [82–84].
Contrary to studies on obesity, a study by Duran et al. found no relationship between
irisin levels and body mass index.  It  was reported that irisin is  a  myokine that gradually
decreases with the formation of glucose intolerance and the progression of T2DM [85]. These
data were supported in many other studies; it was found that FNDC5 mRNA decreased in
patients with T2DM [26] and that irisin decreased significantly [86–88].
In a study conducted in patients diagnosed with T2DM and mild cognitive impairment,
the  level  of  irisin  in  plasma  correlated  with  cognitive  impairment  (especially  executive
function) in T2DM patients. Based on these results, researchers claimed that high irisin levels
in plasma cause clinical early cognitive deficits in patients with T2DM [89].
However, there is no study in the literature examining the relationship between T2DM,
MDB, and irisin comparatively, as in obesity.
Conclusions
Irisin may have undeniable therapeutic potential  on depressive disorders. However,
more clinical studies investigating the association of irisin and its effects on depression are
required. 
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